BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 35508466)

  • 21. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis.
    Hsu HC; Jeng YM; Mao TL; Chu JS; Lai PL; Peng SY
    Am J Pathol; 2000 Sep; 157(3):763-70. PubMed ID: 10980116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
    Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
    Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
    Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
    Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interplay of Wnt β-catenin pathway and miRNAs in HBV pathogenesis leading to HCC.
    Rana MA; Ijaz B; Daud M; Tariq S; Nadeem T; Husnain T
    Clin Res Hepatol Gastroenterol; 2019 Aug; 43(4):373-386. PubMed ID: 30377095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HBx mutations promote hepatoma cell migration through the Wnt/β-catenin signaling pathway.
    Chen Z; Tang J; Cai X; Huang Y; Gao Q; Liang L; Tian L; Yang Y; Zheng Y; Hu Y; Tang N
    Cancer Sci; 2016 Oct; 107(10):1380-1389. PubMed ID: 27420729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteome Characteristics of Non-Alcoholic Steatohepatitis Liver Tissue and Associated Hepatocellular Carcinomas.
    Kakehashi A; Stefanov VE; Ishii N; Okuno T; Fujii H; Kawai K; Kawada N; Wanibuchi H
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation.
    Haines K; Sarabia SF; Alvarez KR; Tomlinson G; Vasudevan SA; Heczey AA; Roy A; Finegold MJ; Parsons DW; Plon SE; López-Terrada D
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27745. PubMed ID: 30977242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DUXAP10 inhibition attenuates the proliferation and metastasis of hepatocellular carcinoma cells by regulation of the Wnt/β-catenin and PI3K/Akt signaling pathways.
    Han K; Li C; Zhang X; Shang L
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30996112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    Torrecilla S; Sia D; Harrington AN; Zhang Z; Cabellos L; Cornella H; Moeini A; Camprecios G; Leow WQ; Fiel MI; Hao K; Bassaganyas L; Mahajan M; Thung SN; Villanueva A; Florman S; Schwartz ME; Llovet JM
    J Hepatol; 2017 Dec; 67(6):1222-1231. PubMed ID: 28843658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study.
    Ando S; Shibahara J; Hayashi A; Fukayama M
    Virchows Arch; 2015 Nov; 467(5):535-42. PubMed ID: 26311355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma.
    Ueno A; Masugi Y; Yamazaki K; Komuta M; Effendi K; Tanami Y; Tsujikawa H; Tanimoto A; Okuda S; Itano O; Kitagawa Y; Kuribayashi S; Sakamoto M
    J Hepatol; 2014 Nov; 61(5):1080-7. PubMed ID: 24946283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De novo HAPLN1 expression hallmarks Wnt-induced stem cell and fibrogenic networks leading to aggressive human hepatocellular carcinomas.
    Mebarki S; Désert R; Sulpice L; Sicard M; Desille M; Canal F; Dubois-Pot Schneider H; Bergeat D; Turlin B; Bellaud P; Lavergne E; Le Guével R; Corlu A; Perret C; Coulouarn C; Clément B; Musso O
    Oncotarget; 2016 Jun; 7(26):39026-39043. PubMed ID: 27191501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach.
    Ozcan M; Altay O; Lam S; Turkez H; Aksoy Y; Nielsen J; Uhlen M; Boren J; Mardinoglu A
    Adv Biosyst; 2020 Jun; 4(6):e2000030. PubMed ID: 32529800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC.
    Charawi S; Just PA; Savall M; Abitbol S; Traore M; Metzger N; Ravinger R; Cavard C; Terris B; Perret C
    J Pathol; 2019 Apr; 247(4):435-443. PubMed ID: 30566242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteogenomic Characterization of Endometrial Carcinoma.
    Dou Y; Kawaler EA; Cui Zhou D; Gritsenko MA; Huang C; Blumenberg L; Karpova A; Petyuk VA; Savage SR; Satpathy S; Liu W; Wu Y; Tsai CF; Wen B; Li Z; Cao S; Moon J; Shi Z; Cornwell M; Wyczalkowski MA; Chu RK; Vasaikar S; Zhou H; Gao Q; Moore RJ; Li K; Sethuraman S; Monroe ME; Zhao R; Heiman D; Krug K; Clauser K; Kothadia R; Maruvka Y; Pico AR; Oliphant AE; Hoskins EL; Pugh SL; Beecroft SJI; Adams DW; Jarman JC; Kong A; Chang HY; Reva B; Liao Y; Rykunov D; Colaprico A; Chen XS; Czekański A; Jędryka M; Matkowski R; Wiznerowicz M; Hiltke T; Boja E; Kinsinger CR; Mesri M; Robles AI; Rodriguez H; Mutch D; Fuh K; Ellis MJ; DeLair D; Thiagarajan M; Mani DR; Getz G; Noble M; Nesvizhskii AI; Wang P; Anderson ML; Levine DA; Smith RD; Payne SH; Ruggles KV; Rodland KD; Ding L; Zhang B; Liu T; Fenyö D;
    Cell; 2020 Feb; 180(4):729-748.e26. PubMed ID: 32059776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
    Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
    Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling.
    Zhao YR; Wang JL; Xu C; Li YM; Sun B; Yang LY
    Clin Sci (Lond); 2019 Jul; 133(14):1645-1662. PubMed ID: 31278131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wnt/Frizzled signaling in hepatocellular carcinoma.
    Lee HC; Kim M; Wands JR
    Front Biosci; 2006 May; 11():1901-15. PubMed ID: 16368566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
    Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
    Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma.
    Akasu M; Shimada S; Kabashima A; Akiyama Y; Shimokawa M; Akahoshi K; Kudo A; Yamaoka S; Tanabe M; Tanaka S
    Sci Rep; 2021 Aug; 11(1):16732. PubMed ID: 34429454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.